References
- Enokida H, Gotanda T, Oku S, . Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn J Cancer Res 2002;93:1037–1046.
- Calatozzolo C, Gelati M, Ciusani E, . Expression of drug resistance proteins P-gp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005;74:113–121.
- Myers MP, Stolarov JP, Eng C, . PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997;94:9052–9057.
- Xu Q, Simpson SE, Scialla TJ, . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102: 972–980.
- Dahia PL, Aguiar RC, Alberta J, . PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in hematological malignancies. Hum Mol Genet 1999; 8:185–193.
- Wang S, Cheng Z, Deng K, . Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. Int J Hematol 2010;92:83–94.
- Zhiyong C, Wentong L, Xiaoyang Y, . PTEN's regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia. Med Oncol 2011 Mar 1. [Epub ahead of print]
- Jotta PY, Ganazza MA, Silva A, . Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010;24:239–242.
- Liu TC, Lin PM, Chang JG, . Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 2000;63:170–175.
- Yang J, Liu J, Zheng J, . A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia. Leukemia 2007;21:2072–2074.
- Montiel-Duarte C, Cordeu L, Agirre X, . Resistance to imatinib mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res 2008;32:709–716.
- Zhang J, Grindley JC, Yin T, . PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006;441:518–522.
- Yilmaz OH, Valdez R, Theisen BK, . Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–482.
- Guo W, Lasky JL, Chang CJ, . Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008;453:529–533.
- Vasudevan KM, Gurvmunhy S, Rangnekar VM. Suppression of PTEN expression by NF-kappaB prevents apoptosis. Mol Cell Biol 2004;24:1007–1021.
- Grandage VL, Gale RE, Linch DC, . PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005;19:586–594.
- Cheng ZY, Guo XL, Yang XY, . PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res 2008;27:87.
- Tabellini G, Cappellini A, Tazzari PL, . Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005;202:623–634.
- Tabellini G, Tazzari PL, Bortul R, . Novel 2’-substituted, 3’-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. Br J Haematol 2004;126:574–582.
- Han Z, Hong L, Han Y, . Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007;26:261–268.
- Yang H, Kong W, He L, . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425–433.
- Zhou M, Gu L, Findley HW, . PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003;63:6357–6362.